>

XTL Biopharmaceuticals Ltd. reported raising $2.5M in a private placement filing on March 1, 2017

Mar 14, 2017 - RelSci Data Update
Investments

Background Information:
XTL Biopharmaceuticals Ltd is a biopharmaceutical company, which engages in the acquisition and development of pharmaceutical drugs. Its drug development program focuses on the treatment of systemic lupus erythematosus. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.
In The News:
XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update
November 1, 2018  •  PR Newswire
XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors
April 27, 2017  •  PR Newswire
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome
February 13, 2017  •  PR Newswire
XTL Biopharmaceuticals Ltd is a biopharmaceutical company, which engages in the acquisition and development of pharmaceutical drugs. Its drug development program focuses on the treatment of systemic lupus erythematosus. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.